52 studies found for:    "Acinic cell carcinoma"
Show Display Options
Rank Status Study
1 Suspended Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: gemcitabine hydrochloride;   Drug: WEE1 inhibitor MK-1775;   Other: placebo;   Other: pharmacological study;   Other: laboratory biomarker analysis
2 Recruiting ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Gallbladder;   Duct Cell Adenocarcinoma of the Pancreas;   Localized Unresectable Adult Primary Liver Cancer;   Periampullary Adenocarcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Gallbladder Cancer;   Recurrent Pancreatic Cancer;   Stage II Gallbladder Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer
Interventions: Drug: ADH-1;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
3 Completed Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: sunitinib malate
4 Recruiting Combination Chemotherapy With or Without Oregovomab Followed By Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Biological: oregovomab;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Drug: fluorouracil
5 Active, not recruiting Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: falimarev;   Biological: inalimarev;   Biological: sargramostim;   Other: laboratory biomarker analysis
6 Recruiting Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer
Interventions: Drug: porfimer sodium;   Procedure: endoscopic ultrasonography;   Procedure: photodynamic therapy;   Drug: gemcitabine hydrochloride
7 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Intraductal Papillary Mucinous Neoplasm of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: erlotinib hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: capecitabine;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
8 Not yet recruiting Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: selinexor;   Other: pharmacological study;   Other: laboratory biomarker analysis
9 Completed Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sorafenib tosylate;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
10 Completed
Has Results
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IV Pancreatic Cancer
Interventions: Drug: bortezomib;   Drug: carboplatin;   Other: laboratory biomarker analysis
11 Active, not recruiting Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: dasatinib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Other: immunohistochemistry staining method
12 Not yet recruiting High-Dose Radiation Therapy Versus Standard Care in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Radiation: intensity-modulated radiation therapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: capecitabine;   Other: laboratory biomarker analysis
13 Withdrawn Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Recurrent Pancreatic Cancer;   Stage IV Breast Cancer;   Stage IV Pancreatic Cancer
Interventions: Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacological study;   Biological: tumor-homing peptide iRGD
14 Recruiting CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
15 Active, not recruiting Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: wild-type reovirus;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis
16 Recruiting Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: 5-fluorouracil;   Drug: capecitabine;   Radiation: radiation;   Procedure: surgery;   Drug: gemcitabine  hydrochloride
17 Active, not recruiting Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: sirolimus;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18
18 Recruiting CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Other: laboratory biomarker analysis
19 Recruiting Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alisertib;   Drug: gemcitabine
20 Not yet recruiting Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage I-III Pancreatic Cancer
Interventions: Drug: metformin hydrochloride;   Radiation: stereotactic radiosurgery

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years